The market is up 1.2% over the last week, and in the past year, it has climbed an impressive 27%, with earnings expected to grow by 17% per annum. Though the term 'penny stock' might sound like a relic of past trading days, these smaller or newer companies can still present significant opportunities when built on solid financials. We've identified three penny stocks that demonstrate financial strength and potential for growth, offering investors a chance to uncover hidden value in quality companies.

Let's take a closer look at a couple of our picks from the screened companies.

Nautilus Biotechnology (NAUT)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Nautilus Biotechnology, Inc. is a development stage life sciences company focused on creating a platform technology to quantify and unlock the complexity of the proteome in the United States, with a market cap of $352.01 million.

Operations: Currently, Nautilus Biotechnology does not report any revenue segments.

Market Cap: $352.01M

Nautilus Biotechnology, with a market cap of US$352.01 million, is pre-revenue and currently unprofitable, reporting a net loss of US$14.7 million for Q1 2026. Despite this, the company maintains a strong cash position with short-term assets of US$98.8 million exceeding liabilities and no debt over the past five years. Management and board members are seasoned with an average tenure of five years, providing stability amid high share price volatility. Recent collaborations like the one with Baylor College of Medicine aim to enhance their proteomics platform's commercial viability through innovative cancer research applications.

GoodRx Holdings (GDRX)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: GoodRx Holdings, Inc. provides tools and information for consumers to compare prices and save on prescription drugs in the United States, with a market cap of approximately $1.04 billion.

Operations: The company generates revenue primarily from its Healthcare Software segment, which reported $787.89 million.

Market Cap: $1.04B

GoodRx Holdings, with a market cap of US$1.04 billion, has shown profitability over the past five years despite recent challenges. The company's revenue primarily stems from its Healthcare Software segment, reporting US$787.89 million in sales. However, recent earnings have declined year-over-year to US$1.17 million for Q1 2026 from US$11.05 million previously, reflecting volatility in performance and profit margins impacted by one-off items like a $14.3 million loss. GoodRx's strategic initiatives include expanding access to GLP-1 medications through partnerships with pharmaceutical companies and enhancing transparency for self-pay patients outside traditional insurance pathways.

Mammoth Energy Services (TUSK)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Mammoth Energy Services, Inc. is an energy services company operating in the United States, Canada, and internationally with a market cap of approximately $162.82 million.

Operations: The company's revenue is primarily derived from its sand ($13.68 million), rentals ($22.14 million), drilling ($4.91 million), accommodations ($10.41 million), and infrastructure ($3.64 million) segments, reflecting a diverse range of service offerings in the energy sector.

Market Cap: $162.82M

Mammoth Energy Services, with a market cap of approximately US$162.82 million, has demonstrated significant revenue growth in recent quarters despite its unprofitability and past earnings decline. The company reported a Q1 2026 revenue increase to US$22.03 million from US$11.63 million the previous year, alongside a net income of US$5.19 million compared to a prior net loss, highlighting improved financial performance. However, challenges persist with high volatility and an inexperienced management team averaging 0.9 years tenure. Recent strategic moves include auditor changes and share buybacks totaling 187,668 shares for US$0.4 million completed by March 2026.

Make It Happen

• Take a closer look at our US Penny Stocks list of 333 companies by clicking here.
• Want To Explore Some Alternatives? Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.